ALX Oncology (ALXO) said Wednesday that it has made certain strategic changes, including reducing its preclinical research budget and cutting its workforce by about 30%, to extend cash runway into Q4 2026.
The company said at its upcoming R&D Day event that it will present the reasons and clinical data supporting further development of evorpacept with anti-cancer antibodies. The company will also share plans for new studies combining evorpacept with trastuzumab for Human Epidermal Growth Factor Receptor 2-positive breast cancer and with cetuximab for colorectal cancer, both starting in H1.
ALX Oncology will also introduce ALX2004, a new antibody-drug conjugate targeting EGFR, which has shown strong anti-tumor activity in early models. The company plans to submit an investigational new drug application for ALX2004 to the Food and Drug Administration in Q1.
The company is making budget and workforce cuts primarily to support these newly planned clinical trial programs in breast cancer and colorectal cancer, it added.
Price: 0.99, Change: -0.01, Percent Change: -1.00
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。